Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Revelation Biosciences (NASDAQ:REVB) Adopts a 10% Poison Pill as REVB Races to Start Its FDA-Agreed Kidney Trial by Year-End

Revelation Biosciences, Inc. (NASDAQ:REVB) is a San Diego clinical-stage biotechnology company with eight full-time employees, noRevenueand under four million shares outstanding. On 10 July 2026 its board adopted a stockholder rights plan, the defensive structure known as a poison pill, triggered at just 10% …

Vinay Lochav | 17 August 2026

SINTX Technologies (NASDAQ:SINT) Clears Nasdaq Equity Test as $3.2 Million in Ceramic Orders Reshape Its Revenue Outlook

SINTX Technologies, Inc. (NASDAQ:SINT) has spent 2026 fighting on two fronts: proving its silicon nitride ceramic can win commercial orders, and proving to Nasdaq that it belongs on the exchange. On 13 August the second fight ended in its favour.

Vinay Lochav | 17 August 2026

Aprea Therapeutics (NASDAQ:APRE) Expands Its WEE1 Trial From Three Sites to Ten as $41.2 Million in Cash Sets Up a Q4 2026 Data Readout

Aprea Therapeutics, Inc. (NASDAQ:APRE) has spent 2026 doing something unusual for a micro-cap biotech: raising money, then immediately spending it on speed. Its second-quarter results, published on 12 August 2026, read less like a routine financial statement than a progress report on a deliberate …

Vinay Lochav | 17 August 2026

Bionano Genomics (NASDAQ:BNGO) Retires Its $20 Million Secured Debt and Lifts 2026 Guidance as Q2 Revenue Jumps 21%

Bionano Genomics, Inc. (NASDAQ:BNGO) has spent two years shrinking in order to survive. On 10 August 2026 the San Diego company reported second-quarter results showing the other side of that process: revenue growing again, grossMarginabove 50%, and no securedDebton the balance sheet.

Vinay Lochav | 17 August 2026

Aclarion (NASDAQ:ACON) Stock: Board Rejects $4 Buyout, Trades Below Cash Value

Aclarion, Inc. (NASDAQ:ACON) has an unusual problem: an activist investor tried to buy the company for more than the market would pay, and the board said no. The ColoradoMedTechsells Nociscan, a magnetic resonance spectroscopy (MRS) test that reads chemical signals inside spinal discs to …

Vinay Lochav | 17 August 2026

Why Is Snap (NYSE:SNAP) Stock Down in Pre-Market Trading?

Snap (NYSE:SNAP) shares fell 4.80% in pre-market trading to $5.16, down from a prior close of $5.41, extending a difficult stretch that has seen the stock fall 45% from its 2025 highs amid persistent brand advertising headwinds, disappointing user growth, and skepticism around monetization …

Nitish Kishor | 17 August 2026

Why Is Astera Labs (NASDAQ:ALAB) Stock Up 7% in Pre-Market Trading?

Astera Labs (NASDAQ:ALAB) shares rose 6.58% in pre-market trading to $342.76, up from a prior close of $321.61, as investors continue to digest strong institutional buying interest following the company's second quarterEarningsreport. Amazon (NASDAQ:AMZN) disclosed a new 277,777-share stake, worth approximately $134 million, in …

Nitish Kishor | 17 August 2026

Why Is Intuitive Machines (NASDAQ:LUNR) Stock Up in Pre-Market Trading?

Intuitive Machines (NASDAQ:LUNR) shares rose 4.03% in pre-market trading to $19.78, up from a prior close of $19.01, after the company announced it received authorization to proceed from an undisclosed customer to begin work on a multi-satellite communications infrastructure program with an anticipated value …

Nitish Kishor | 17 August 2026

Why Is Keel Infrastructure (NASDAQ:KEEL) Stock Rising in Pre-Market Trading?

Keel Infrastructure (NASDAQ:KEEL), formerly Bitfarms, shares rose 5.98% in pre-market trading to $3.72, up from a prior close of $3.51, extending gains from Friday's close as investors continue to respond positively to Chief Executive Officer Benjamin Gagnon's insider purchase of nearly 59,000 shares, worth …

Nitish Kishor | 17 August 2026

Why Is Netskope (NASDAQ:NTSK) Stock Down in Pre-Market Trading?

Netskope (NASDAQ:NTSK) shares fell 3.86% in pre-market trading to $15.20, down from a prior close of $15.81, falling roughly 4% and extending recentVolatilitythat followed a sharp post-earnings selloff earlier this week despite cautious full-year 2027 guidance following an otherwise solid fourth quarter beat.

Nitish Kishor | 17 August 2026
Support

Hi! How can we help you today?

Loading…